| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | erlotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.077 | 0.04 |
| mRNA | BRD6340 | CTRPv2 | pan-cancer | AAC | 0.071 | 0.04 |
| mRNA | tivozanib | GDSC1000 | pan-cancer | AAC | 0.069 | 0.04 |
| mRNA | SU11274 | CTRPv2 | pan-cancer | AAC | -0.072 | 0.04 |
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | 0.09 | 0.04 |
| mRNA | Irinotecan | CCLE | pan-cancer | AAC | -0.1 | 0.04 |
| mRNA | JQ12 | GDSC1000 | pan-cancer | AAC | 0.07 | 0.05 |
| mRNA | BRD-K78574327 | CTRPv2 | pan-cancer | AAC | 0.15 | 0.05 |
| mRNA | PLX4720 | GDSC1000 | pan-cancer | AAC | -0.061 | 0.05 |
| mRNA | MPS-1-IN-1 | GDSC1000 | pan-cancer | AAC | -0.063 | 0.05 |